PURPOSE: External beam radiotherapy (EBRT) after conservative surgery for early breast cancer requires 5-7 weeks. For elderly patients and those distant from an RT center, attending for EBRT may be difficult or impossible. We investigated local toxicity, cosmetic outcomes, and quality of life in a new breast irradiation technique-intraoperative avidination for radionuclide therapy (IART)-in which avidin is administered to the tumor bed and (90)Y-labelled biotin later administered intravenously to bind the avidin and provide irradiation. Reduced duration EBRT (40 Gy) is given subsequently. METHODS: After surgery, 50 (ten patients), 100 (15 patients) or 150 mg (ten patients) of avidin was injected into the tumor bed. After 12-24 h, 3.7 GBq (90)Y-biotin (beta source for therapeutic effect) plus 185 MBq (111)In-biotin (gamma source for imaging and dosimetry) was infused slowly. Whole-body scintigraphy and SPECT/CT images were taken for up to 30 h. Shortened EBRT started 4 weeks later. Local toxicity was assessed by RTOG scale; quality of life was assessed by EORTC QOL-30. RESULTS: Of 35 patients recruited (mean age 63 years; range 42-74) 32 received IART plus EBRT. 100 mg avidin provided 19.5 +/- 4.0 Gy to the tumor bed and was considered the optimum dose. No side-effects of avidin or (90)Y-biotin occurred, with no hematological or local toxicity. Local G3 toxicity occurred in 3/32 patients during EBRT. IART plus EBRT was well accepted, with good cosmetic outcomes and maintained quality of life. CONCLUSIONS: IART plus reduced EBRT can accelerate irradiation after conservative breast surgery.
PURPOSE: External beam radiotherapy (EBRT) after conservative surgery for early breast cancer requires 5-7 weeks. For elderly patients and those distant from an RT center, attending for EBRT may be difficult or impossible. We investigated local toxicity, cosmetic outcomes, and quality of life in a new breast irradiation technique-intraoperative avidination for radionuclide therapy (IART)-in which avidin is administered to the tumor bed and (90)Y-labelled biotin later administered intravenously to bind the avidin and provide irradiation. Reduced duration EBRT (40 Gy) is given subsequently. METHODS: After surgery, 50 (ten patients), 100 (15 patients) or 150 mg (ten patients) of avidin was injected into the tumor bed. After 12-24 h, 3.7 GBq (90)Y-biotin (beta source for therapeutic effect) plus 185 MBq (111)In-biotin (gamma source for imaging and dosimetry) was infused slowly. Whole-body scintigraphy and SPECT/CT images were taken for up to 30 h. Shortened EBRT started 4 weeks later. Local toxicity was assessed by RTOG scale; quality of life was assessed by EORTC QOL-30. RESULTS: Of 35 patients recruited (mean age 63 years; range 42-74) 32 received IART plus EBRT. 100 mg avidin provided 19.5 +/- 4.0 Gy to the tumor bed and was considered the optimum dose. No side-effects of avidin or (90)Y-biotin occurred, with no hematological or local toxicity. Local G3 toxicity occurred in 3/32 patients during EBRT. IART plus EBRT was well accepted, with good cosmetic outcomes and maintained quality of life. CONCLUSIONS: IART plus reduced EBRT can accelerate irradiation after conservative breast surgery.
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: E Lazzeri; M Manca; N Molea; S Marchetti; V Consoli; L Bodei; R Bianchi; M Chinol; G Paganelli; G Mariani Journal: Eur J Nucl Med Date: 1999-06
Authors: Jayant S Vaidya; Jeffrey S Tobias; Michael Baum; Frederik Wenz; Uta Kraus-Tiefenbacher; Derek D'souza; Mohammed Keshtgar; Samuele Massarut; Basil Hilaris; Christobel Saunders; David Joseph Journal: Semin Radiat Oncol Date: 2005-04 Impact factor: 5.934
Authors: David M Goldenberg; Robert M Sharkey; Giovanni Paganelli; Jacques Barbet; Jean-François Chatal Journal: J Clin Oncol Date: 2005-12-27 Impact factor: 44.544
Authors: Giovanni Paganelli; Mahila Ferrari; Laura Ravasi; Marta Cremonesi; Concetta De Cicco; Viviana Galimberti; Gregory Sivolapenko; Alberto Luini; Rita De Santis; Laura Lavinia Travaini; Maurizio Fiorenza; Marco Chinol; Stefano Papi; Claudio Zanna; Paolo Carminati; Umberto Veronesi Journal: Clin Cancer Res Date: 2007-09-15 Impact factor: 12.531
Authors: Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Mélanie Recordon; Angelika Bischof-Delaloye; George Sgouros Journal: Cancer Biother Radiopharm Date: 2008-10 Impact factor: 3.099
Authors: Barry W Wessels; Mark W Konijnenberg; Roger G Dale; Hazel B Breitz; Marta Cremonesi; Ruby F Meredith; Alan J Green; Lionel G Bouchet; A Bertrand Brill; Wesley E Bolch; George Sgouros; Stephen R Thomas Journal: J Nucl Med Date: 2008-10-16 Impact factor: 10.057
Authors: Shihong Li; Beth Goins; William T Phillips; Marcela Saenz; Pamela M Otto; Ande Bao Journal: Breast Cancer Res Treat Date: 2010-12-23 Impact factor: 4.872
Authors: Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-03 Impact factor: 9.236
Authors: Ferdinando Maria Milazzo; Anna Maria Anastasi; Caterina Chiapparino; Antonio Rosi; Barbara Leoni; Loredana Vesci; Fiorella Petronzelli; Rita De Santis Journal: Oncotarget Date: 2017-04-04
Authors: Claudius Melzig; Azadeh Fahim Golestaneh; Walter Mier; Christian Schwager; Samayita Das; Julian Schlegel; Felix Lasitschka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn; Amir Abdollahi Journal: Oncotarget Date: 2018-07-06